Aptamer 学术简报 — neurodegeneration — 2026-07-22

自动生成 by RBTX Aptamer Tracker v0.1。 子主题 neurodegeneration：近 14 天 12 篇命中（aptamer 池 171 篇）。

评分公式：composite = 0.45×log(IF) + 0.35×log(cites_velocity) + 0.10×social + 0.10×recency_bonus；满分 100。

#1 [14.7] Radical‐Mediated In Situ Fluorescence Dye Deposition: A Simple Interfacial Signal Amplification Reaction for Ultrasensitive Immunoassay on Barcode Beads

Ultrasensitive detection of low-abundance protein biomarkers is crucial for early disease diagnosis but remains challenging for the conventional barcode beads-based suspension chip platform due to the limited detection sensitivity. Here, we report a conceptually novel reaction termed "radical-mediated in situ fluorescence dye deposition" (RIFD) ...

#2 [13.1] Development of an RNA aptamer as a therapeutic agent for synucleinopathies.

The aggregation of α-synuclein (αSyn), a 140-mer protein, has been implicated in the pathogenesis of Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies. KTKEGV pseudo-repeats (KRs) in the sequence of αSyn are key mediators of its prion-like propagation and neurodegeneration. Despite the availability of symptomatic treatm...

#3 [10.5] Ultrasensitive electrochemiluminescence aptasensor for Tau protein based on gold nanoparticle-modified perovskite nanocrystals.

Early diagnosis for Alzheimer's disease (AD) is vital for effective therapeutic intervention and improved patient prognosis. In this work, we developed a highly sensitive electrochemiluminescence (ECL) aptasensor for detecting a key AD biomarker, Tau protein. An all-inorganic perovskite CsPbBr3 nanocrystals (NCs) were used as ECL emitters and we...

#4 [9.0] An aptamer targeting TfR1 enhances ASO delivery to muscle tissue

Oligonucleotide based therapeutics continue to rise as a significant class of medicines for the treatment of human disease. However, achieving delivery to non-hepatic tissues remains a challenge in the field. While substantial advances have been realized, largely through the use of antibody or protein based targeting agents to tissues including ...

#5 [9.0] An aptamer-mediated EXPAR fluorescence biosensor for early and sensitive detection of Aβ42 and Aβ40.

BACKGROUND: Alzheimer's disease (AD) is a common neurodegenerative disorder with increasing cases worldwide. Early screening is important for AD prevention and treatment, but current methods still face many challenges. RESULTS: To address these challenges, we developed a simple and novel molecular beacon (MB) fluorescent biosensor. This sensor c...

#6 [8.1] NMR characterization of the structure and interaction of an RNA aptamer targeting α-synuclein.

α-Synuclein (αSyn) is an intrinsically disordered protein whose aberrant aggregation is a hallmark of Parkinson's disease. C-terminally truncated αSyn variants promote aggregation and fibril formation of full-length αSyn, making them targets for diagnosis and therapy. sh1R6 is an RNA aptamer selected against a C-terminally truncated αSyn variant...

#7 [8.0] Metal nanostructure‐coupled label‐free localized surface plasmon resonance biosensors for rapid and sensitive disease diagnosis

Abstract Localized surface plasmon resonance (LSPR) technology is capable of detecting biomarkers in biological samples quickly and accurately outside the lab. LSPR is highly sensitive to the dielectric environment on the surface of metal nanostructures and can detect biomolecular binding through real‐time wavelength shift measurements. It is su...

#8 [7.7] Liquid crystal biosensing platform based on whispering gallery mode laser for Aβ42 detection.

Alzheimer's disease (AD) is an irreversible and progressively worsening neurodegenerative disorder. Amyloid beta (Aβ42) plays a crucial role in the early diagnosis of this disease. However, the concentration of Aβ42 in the blood is extremely low, which poses a challenge for Aβ42 detection. Herein, a liquid crystal (LC) biosensing platform based ...

#9 [6.0] Longitudinal plasma proteomics separates diagnostic differences from progression-linked changes in Alzheimer's disease.

Most plasma proteomic studies in Alzheimer's disease (AD) compare cases and controls cross-sectionally, leaving unresolved which AD-associated proteins mark diagnostic states and which are linked to disease progression. Using longitudinal SomaScan profiling from the Global Neurodegeneration Proteomics Consortium (13,449 participants, 17,269 samp...

#10 [5.3] SELEX to Clinic: Evolution, Innovations and Applications of Aptamers in Precision Medicine

Aptamers are short, single-stranded DNA or RNA oligonucleotides selected in vitro via SELEX (Systematic Evolution of Ligands by Exponential Enrichment) that fold into defined 3-D structures and bind cognate targets with antibody-like affinity yet superior versatility. Thirty-five years after their simultaneous disclosure by Ellington & Szostak a...

Methodology